相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Catechol enhances chemo- and radio-sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells
Jeong Yong Moon et al.
ONCOLOGY REPORTS (2021)
LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma
Yasuyuki Okada et al.
CARCINOGENESIS (2021)
Cell-programmed nutrient partitioning in the tumour microenvironment
Bradley Reinfeld et al.
NATURE (2021)
Harnessing metabolic dependencies in pancreatic cancers
Joel Encarnacion-Rosado et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Arginine Signaling and Cancer Metabolism
Chia-Lin Chen et al.
CANCERS (2021)
Targeting FAK in anticancer combination therapies
John C. Dawson et al.
NATURE REVIEWS CANCER (2021)
Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism
Ilaria Elia et al.
NATURE METABOLISM (2021)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
BRITISH JOURNAL OF CANCER (2020)
Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers
Suman Mukhopadhyay et al.
CANCER RESEARCH (2020)
A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells
Hee Chan Yoo et al.
CELL METABOLISM (2020)
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy
Nikita S. Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Metabolism of pancreatic cancer: paving the way to better anticancer strategies
Cheng Qin et al.
MOLECULAR CANCER (2020)
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer
Austin R. Dosch et al.
MOLECULAR CANCER RESEARCH (2020)
Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer
Ashenafi Bulle et al.
TRANSLATIONAL ONCOLOGY (2020)
Macropinocytosis confers resistance to therapies targeting cancer anabolism
Vaishali Jayashankar et al.
NATURE COMMUNICATIONS (2020)
Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells
Omar Elaskalani et al.
CANCERS (2020)
Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells
Leontine Sandforth et al.
CANCERS (2020)
The Generation and Identity of Human Myeloid-Derived Suppressor Cells
Caroline Bergenfelz et al.
FRONTIERS IN ONCOLOGY (2020)
A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors
Paul C. McDonald et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer
Huocong Huang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2020)
Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
Zhihong Xu et al.
BRITISH JOURNAL OF CANCER (2020)
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
Herbert J. Zeh et al.
CLINICAL CANCER RESEARCH (2020)
Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer
Mohammad Aslam Khan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling
Yunjiang Zhou et al.
REDOX BIOLOGY (2020)
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Keisuke Yamamoto et al.
NATURE (2020)
T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?
Qi Zhou et al.
FRONTIERS IN ONCOLOGY (2020)
The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities
Won Jin Ho et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation
Francesca Ricciardiello et al.
ONCOGENE (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
Ruth M. Escalona et al.
BMC CANCER (2020)
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Albrecht Neesse et al.
GUT (2019)
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors
Bethany C. Prudner et al.
CLINICAL CANCER RESEARCH (2019)
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia
Paul C. McDonald et al.
GASTROENTEROLOGY (2019)
Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer
Yuanyuan Pei et al.
SMALL (2019)
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer A Phase 2 Randomized Clinical Trial
Thomas B. Karasic et al.
JAMA ONCOLOGY (2019)
Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells
Manoj Amrutkar et al.
BMC CANCER (2019)
Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer
Yuan Fang et al.
EXPERIMENTAL CELL RESEARCH (2019)
Chemoresistance in Pancreatic Cancer
Siyuan Zeng et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Hyaluronan-CD44 axis orchestrates cancer stem cell functions
Spyros S. Skandalis et al.
CELLULAR SIGNALLING (2019)
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Robert D. Leone et al.
SCIENCE (2019)
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
Michael Timaner et al.
CANCER RESEARCH (2018)
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Adam J. Camblin et al.
CLINICAL CANCER RESEARCH (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Reham Abdel-Wahab et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer
Christopher C. M. Neumann et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
Jun Gong et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
TGFβ promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1
P-H Huang et al.
ONCOGENE (2017)
Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells
K. E. Richards et al.
ONCOGENE (2017)
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
Vincent J. Picozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Marianne Sinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Daniel Ohlund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Gary Middleton et al.
LANCET ONCOLOGY (2017)
Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy
Richard L. Sleightholm et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Hippo pathway mediates resistance to cytotoxic drugs
Taranjit S. Gujral et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)
Kit Man Wong et al.
CURRENT ONCOLOGY REPORTS (2017)
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
Ru Chen et al.
SCIENTIFIC REPORTS (2017)
The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance
Omar Elaskalani et al.
CANCERS (2017)
A Phase 1/1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Maeve A. Lowery et al.
CANCER (2017)
Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer
Zenobia D'Costa et al.
CANCER RESEARCH (2017)
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer
Surendra K. Shukla et al.
CANCER CELL (2017)
Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages
Lutian Yao et al.
CYTOKINE (2017)
Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis
Guozhe Xian et al.
CANCER LETTERS (2017)
HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy
Tongzheng Liu et al.
CANCER RESEARCH (2016)
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3
Rachel A. Hesler et al.
CARCINOGENESIS (2016)
CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy
Shujie Zhao et al.
CLINICAL CANCER RESEARCH (2016)
Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma
Christopher C. DuFort et al.
GASTROENTEROLOGY (2016)
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion
Cristovao M. Sousa et al.
NATURE (2016)
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang et al.
NATURE MEDICINE (2016)
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin
Dietmar Zechner et al.
ONCOTARGET (2016)
Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling
Bao-Qing Xu et al.
ONCOTARGET (2016)
Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer
Jiyoon Lee et al.
NEOPLASIA (2016)
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
C. S. Fuchs et al.
ANNALS OF ONCOLOGY (2015)
Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma
Brian A. Boone et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival (vol 25, pg 719, 2014)
Berna C. Oezdemir et al.
CANCER CELL (2015)
Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer
Shintaro Takeuchi et al.
CANCER RESEARCH (2015)
Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer
Nagaraj S. Nagathihalli et al.
GASTROENTEROLOGY (2015)
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Albrecht Neesse et al.
GUT (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist
Sangjun Lee et al.
MOLECULAR ONCOLOGY (2015)
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer
Feng Cao et al.
ONCOLOGY REPORTS (2015)
A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer
Jai-Hee Moon et al.
ONCOTARGET (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
S. Pant et al.
ANNALS OF ONCOLOGY (2014)
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer
Rouzbeh Daylami et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase
N. Weizman et al.
ONCOGENE (2014)
Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer
P. P. Provenzano et al.
BRITISH JOURNAL OF CANCER (2013)
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
Jonathan B. Mitchem et al.
CANCER RESEARCH (2013)
Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression
Surabhi Dangi-Garimella et al.
PLOS ONE (2013)
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
Albrecht Neesse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman et al.
AGING-US (2011)
Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP-Mediated Expression of HMGA2
Surabhi Dangi-Garimella et al.
CANCER RESEARCH (2011)
Pancreatic cancers require autophagy for tumor growth
Shenghong Yang et al.
GENES & DEVELOPMENT (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
S. Singh et al.
BRITISH JOURNAL OF CANCER (2010)
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines
Wu Huanwen et al.
MOLECULAR CANCER (2009)
HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy
Heike Summer et al.
NUCLEIC ACIDS RESEARCH (2009)
Vaccines in cancer:: GVAX®, a GM-CDF gene vaccine
John Nemunaitis
EXPERT REVIEW OF VACCINES (2005)
Desmoplastic reaction in pancreatic cancer - Role of pancreatic stellate cells
MV Apte et al.
PANCREAS (2004)
分享论文
